Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise
Public ClinicalTrials.gov record NCT03353350. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Primary Objective: To demonstrate the superiority of once weekly injection of efpeglenatide in comparison to placebo in glycated hemoglobin (HbA1c) change in participants with T2DM (Type 2 Diabetes Mellitus) inadequately controlled with diet and exercise. Secondary Objectives: * To demonstrate the superiority of once-weekly injection of efpeglenatide in comparison to placebo on glycemic control * To demonstrate the superiority of once-weekly injection of efpeglenatide in comparison to placebo on body weight * To evaluate the safety of once-weekly injection of efpeglenatide
Study identification
- NCT ID
- NCT03353350
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 406 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 5, 2017 (Actual)
- Primary completion
- Jan 29, 2020 (Actual)
- Completion
- Sep 7, 2020 (Actual)
- Last update posted
- Jan 18, 2022
2017 – 2020
United States locations
- U.S. sites
- 32
- U.S. states
- 15
- U.S. cities
- 29
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigational Site Number 8400004 | Birmingham | Alabama | 35205 | — |
| Investigational Site Number 8400005 | Glendale | Arizona | 85306 | — |
| Investigational Site Number 8400003 | Canoga Park | California | 91303 | — |
| Investigational Site Number 8400007 | Chula Vista | California | 91911 | — |
| Investigational Site Number 8400011 | La Mesa | California | 91942 | — |
| Investigational Site Number 8400009 | Los Angeles | California | 90057 | — |
| Investigational Site Number 8400029 | Pomona | California | 91767 | — |
| Investigational Site Number 8400024 | Tarzana | California | 91356 | — |
| Investigational Site Number 8400026 | Van Nuys | California | 91405 | — |
| Investigational Site Number 8400010 | DeLand | Florida | 32720 | — |
| Investigational Site Number 8400006 | Hialeah | Florida | 33012 | — |
| Investigational Site Number 8400032 | West Palm Beach | Florida | 33409 | — |
| Investigational Site Number 8400025 | Lawrenceville | Georgia | 30044 | — |
| Investigational Site Number 8400034 | Chicago | Illinois | 60612 | — |
| Investigational Site Number 8400033 | Kansas City | Missouri | 64128 | — |
| Investigational Site Number 8400018 | Lincoln | Nebraska | 68503 | — |
| Investigational Site Number 8400062 | Las Vegas | Nevada | 89106 | — |
| Investigational Site Number 8400021 | Las Vegas | Nevada | 89109 | — |
| Investigational Site Number 8400001 | Bridgeton | New Jersey | 08302 | — |
| Investigational Site Number 8400028 | Burlington | North Carolina | 27215 | — |
| Investigational Site Number 8400031 | Wilmington | North Carolina | 28401 | — |
| Investigational Site Number 8400013 | Maumee | Ohio | 43537 | — |
| Investigational Site Number 8400008 | Hatboro | Pennsylvania | 19040 | — |
| Investigational Site Number 8400017 | Carrollton | Texas | 75010 | — |
| Investigational Site Number 8400030 | Dallas | Texas | 75230 | — |
| Investigational Site Number 8400015 | Houston | Texas | 77074 | — |
| Investigational Site Number 8400019 | Plano | Texas | 75024 | — |
| Investigational Site Number 8400020 | San Antonio | Texas | 78218 | — |
| Investigational Site Number 8400016 | San Antonio | Texas | 78229 | — |
| Investigational Site Number 8400027 | San Antonio | Texas | 78229 | — |
| Investigational Site Number 8400023 | Schertz | Texas | 78154 | — |
| Investigational Site Number 8400002 | Holladay | Utah | 84117-7054 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03353350, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 18, 2022 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03353350 live on ClinicalTrials.gov.